

Date: March 30, 2022

To, To,

BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400 051

Ref.: BSE Scrip Code No. "533138" Ref.: NSE Symbol "ASTEC"

Dear Sir / Madam,

Sub.: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit Rating by ICRA Limited for Rs.300 Crore Commercial Paper programme of Astec LifeSciences Limited (enhanced from Rs.200 Crore)

Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), this is to inform you that ICRA Limited, vide its letter dated March 29, 2022, has:

- i. Assigned "ICRA A1+" rating (pronounced 'ICRA A one plus') to the enhanced Commercial Paper programme of Rs. 100 Crore (Rupees One Hundred Crore Only) of the Company; and
- ii. Re-affirmed its "ICRA A1+" rating (pronounced as 'ICRA A one plus') to the existing Rs.200 Crore (Rupees Two Hundred Crore Only) Commercial Paper programme of the Company.

Considering the above, the credit rating assigned by ICRA Limited to the Company for its entire Commercial Paper programme of Rs. 300 Crore (Rupees Three Hundred Crore Only) is "ICRA A1+" rating (pronounced as 'ICRA A one plus').

Further, pursuant to Regulation 30(8) of the SEBI Regulations, this intimation will also made available on the Company's website at www.astecls.com.

Kindly take the above on your records.

Yours faithfully,

For Astec LifeSciences Limited

Tejashree Pradhan Company Secretary & Compliance Officer (FCS 7167)

Encl.: As above





